FDA Approves ZIPRASIDONE — Chartwell RX, LLC

# FDA Approval Newswire The FDA has approved Chartwell RX, LLC's generic formulation of Ziprasidone Hydrochloride for oral administration, expanding the competitive landscape in the atypical antipsychotic market and potentially increasing price pressure on branded alternatives. The approval of this ANDA application is expected to provide healthcare providers and patients with a more cost-effective treatment option for schizophrenia and bipolar disorder management.